Tag Archives: Johnson & Johnson

New Prostate Cancer Drug Approved by FDA

Good news for patients with metastatic prostate cancer.  The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy.  Abiraterone … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , | 1 Comment